Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1473 • 2017 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In Germany no prospective data are available for Golimumab (GLM) in patients with RA, AS and PsAregarding outcomes evaluating work productivity and activity in…
Abstract Number: 1547 • 2017 ACR/ARHP Annual Meeting
Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)
Jun Won Park¹, Jin Kyun Park¹, Kichul Shin², Yong-Beom Park³, Eun Bong Lee¹, Yeong Wook Song⁴ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…
Abstract Number: 2511 • 2017 ACR/ARHP Annual Meeting
Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?
Tor Olofsson¹, Elisabeth Mogard¹, Jan Marsal², Mats Geijer³, Lars Erik Kristensen⁴, Elisabet Lindqvist¹ and Johan K Wallman⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences Lund, Gastroenterology, Lund University, Lund, Sweden, ³Department of Radiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ⁴Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁵Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden
Background/Purpose: While inflammatory bowel disease (IBD) is a well-known comorbidity in axial spondyloarthritis (SpA), little is known about functional bowel problems, such as irritable bowel…
Abstract Number: 1512 • 2017 ACR/ARHP Annual Meeting
Is Sacroiliac Imaging the All-Decisive Factor in the Diagnosis of Early Axial Spondyloarthritis? Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Zineb Ez-Zaitouni¹, Robert B.M. Landewé², Miranda van Lunteren¹, Pauline Bakker¹, Karen M Fagerli³, Roberta Ramonda⁴, Lennart TH Jacobsson⁵, Désirée van der Heijde⁶ and Floris van Gaalen⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, University of Padova, Padova, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Imaging of the sacroiliac joints plays a pivotal role in the recognition of axSpA. However, interpretation of imaging is challenging and has led to…
Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Roger A. Levy¹, Vanessa Teich², Roberta Fernandes², Anna Gulart², Leonardo Chaves³, Vishvas Garg⁴ and Martha Skup⁵, ¹Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Sense Company, São Paulo, Brazil, ³AbbVie Inc., Chicago, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
Abstract Number: 715 • 2016 ACR/ARHP Annual Meeting
Are Patients with Ankylosing Spondylitis Willing to Pay for Treatment with Infliximab?
Casper Webers^1,2, Ivette Essers^1,2, Astrid van Tubergen^1,2, Jürgen Braun³, Frank Heldmann⁴, Xenofon Baraliakos⁵ and Annelies Boonen^2,6, ¹Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Zeisigwaldkliniken Bethanien, Chemnitz, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In view of the continuous pressure of biologicals on healthcare budgets, it is essential to assess the value of biologicals for patients from different…
Abstract Number: 1426 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Prashanth Sunkureddi¹, Dawn Gibson², Stephen Doogan³, John Heid⁴, Samir Benosman⁵ and Yujin Park⁶, ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²The Global Healthy Living Foundation, Upper Nyack, NY, ³Real Life Sciences, New York, NY, ⁴Kinapse, Inc, London, United Kingdom, ⁵Advisory Services, Kinapse, Inc, London, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spinal joints that can lead to severe, chronic pain and discomfort. There is a…
Abstract Number: 2177 • 2016 ACR/ARHP Annual Meeting
Specificity of Spinal Pain Features in Assessment and Classification of Spondyloarthritis
Sjef Van Der Linden¹, Heinz Baumberger² and Muhammad Asim Khan³, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²N.A., Swiss Ankylosing Spondylitis Patient Society, 7017 Flims Dorf, Switzerland, ³Medicine/ Rheumatology, Case Western Reserve Univ, Cleveland, OH
Background/Purpose: Classification criteria lacking specificity cause inclusion of many false positives in settings with low prevalence of disease. The ASAS axial spondyloarthritis (axSpA) criteria have…
Abstract Number: 3155 • 2016 ACR/ARHP Annual Meeting
Zygapophyseal Joint Fusion in Ankylosing Spondylitis Assessed Using Computed Tomography: Associations with Syndesmophytes and Spinal Motion
Sovira Tan¹, Jianhua Yao², Lawrence Yao³, John Flynn⁴ and Michael Ward¹, ¹NIAMS/NIH, Bethesda, MD, ²Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, ³Radiology and Imaging Sciences, NIH, Bethesda, MD, ⁴Dept of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Both zygapophyseal joint (ZJ) fusion and syndesmophytes contribute to structural spine damage in Ankylosing Spondylitis (AS). However, because ZJs are difficult to visualize on…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 716 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors
Susanne Juhl Pedersen¹, Ulrich Weber², Roula Said Nahal³, Inge Juul Sorensen¹, Anne Gitte Loft⁴, Niels Tvede¹, Gina Kollerup¹, Lars Juul¹, Gorm Thamsborg¹, Ole Rintek Madsen¹, Jakob M. Møller⁵, Lone Balding⁶, Anne Grethe Jurik⁷ and Mikkel Østergaard⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ³Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, ⁷Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark
Background/Purpose: Only few studies have investigated long-term radiographic progression in the spine of patients with ankylosing spondylitis (AS). Moreover, no studies have reported changes in…
Abstract Number: 1427 • 2016 ACR/ARHP Annual Meeting
The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort
Sergio Schwartzman¹, Keith Knapp², Gary Craig³ and Discus, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest PLLC., Spokane, WA, ³Discus Analytics LLC., Spokane, WA
Background/Purpose: Outcome measures in AS are well established in clinical trial settings but infrequently used in real-world (RW) practice. These measures include the BASDAI, BASFI,…
Abstract Number: 2442 • 2016 ACR/ARHP Annual Meeting
Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Neda Amiri¹, Gretchen Bandoli², Diana L Johnson² and Christina D. Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Use of Nonsteroidal Anti-inflammatory Drugs in Pregnant Women with Inflammatory Arthritis Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in the third trimester of pregnancy…
Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Klaus Krüger¹, GR Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius, München, Germany, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumazentrum, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…
Abstract Number: 717 • 2016 ACR/ARHP Annual Meeting
NSAID Use and Functional Impairment in Ankylosing Spondylitis
Mark Hwang¹, Seth Eisen¹, MinJae Lee², Michael Ward³, Lianne S. Gensler⁴, Prabha Ranganathan⁵, Johnathan Jia⁶, Amirali Tahanan², Matthew A. Brown⁷, Mohammad H. Rahbar², Michael Weisman⁸ and John D. Reveille⁹, ¹Internal Medicine-Rheumatology, Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ⁶University of Texas-McGovern Medical School, Houston, TX, ⁷The University of Queensland Diamantina Institute, Brisbane, Australia, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with significant burden to patients and society. NSAIDs are the first line pharmacologic therapy in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].